Skip to main content
placeholder image

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2011

Citation


  • Jotte, R., Von Pawel, J., Spigel, D. R., Socinski, M. A., O'Brien, M., Paschold, E. H., . . . Renschler, M. F. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology, 29(15_suppl), 7000. doi:10.1200/jco.2011.29.15_suppl.7000

Web Of Science Accession Number


Start Page


  • 7000

End Page


  • 7000

Volume


  • 29

Issue


  • 15_suppl

Place Of Publication


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2011

Citation


  • Jotte, R., Von Pawel, J., Spigel, D. R., Socinski, M. A., O'Brien, M., Paschold, E. H., . . . Renschler, M. F. (2011). Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).. Journal of Clinical Oncology, 29(15_suppl), 7000. doi:10.1200/jco.2011.29.15_suppl.7000

Web Of Science Accession Number


Start Page


  • 7000

End Page


  • 7000

Volume


  • 29

Issue


  • 15_suppl

Place Of Publication